• PATH completes phase 3 (b) of Bangladesh clinical trial

Bioanalytical

PATH completes phase 3 (b) of Bangladesh clinical trial

Dec 18 2012

International non-profit organisation PATH has completed phase 3 (b) of a new clinical trial in Bangladesh, where they are investigating the antibiotic Paromomycin Intramuscular Injection (PMIM).

It has been developed in an effort to treat visceral leishmaniasis (VL or kala-azar), with the work looking at the safety and efficacy of PMIM mono-therapy across 120 patients in areas of the country where the disease is present.

The trial's first patient was enrolled in January 2011 and, since then, government-run public health centres, expert researchers and scientists at the Centre for Communicable Diseases have worked together to improve understanding of the deadly illness.

VL is an infectious disease that is transmitted through the bite of a sand fly and can go on to affect visceral organs, leading to chronic fever, weight loss and anemia.

In an effort to combat VL, PMIM was developed by OneWorld Health and the treatment has been recommended by the World Health Organisation as the preferred combination therapy to treat the disease in South Asia.

As well as this, PMIM is registered with drug regulatory agencies in India, Nepal and Uganda.

Dr Ponni Subbiah, global program leader for PATH’s drug development group, said: "Our model for administering PMIM in this study allowed patients to receive testing and treatment in an outpatient setting. This has worked well for those patients who live in rural and remote areas where VL is endemic.

"It is wonderful to know that the drug we developed can contribute to the ongoing efforts to evaluate, strengthen, and expand the arsenal of available treatments for VL."

Elsewhere in the pharma world, Avaxia Biologics Inc recently announced the US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for AVX-470.

The biotechnology company engineers oral antibody drugs and this consent will allow it to use AVX-470 in trials for ulcerative colitis treatment.

AVX-470 is an anti-TNF (tumour necrosis factor) polyclonal antibody and is the first clinical contender to emerge from the business' oral antibody platform.

Posted by Ben Evans


Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions

Events

EuCheMS Chemistry Congress

Jul 07 2024 Dublin, Ireland

HPLC 2024

Jul 20 2024 Denver, CO, USA

ICMGP 2024

Jul 21 2024 Cape Town, South Africa

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

JASIS 2024

Sep 04 2024 Chiba, Tokyo, Japan

View all events